What it's for (Indications)
- Mitomycin is an antineoplastic antibiotic primarily indicated for the treatment of disseminated adenocarcinoma of the stomach or pancreas, often used in combination with other chemotherapeutic agents.
- It is also extensively utilized for the management of superficial bladder cancer through intravesical instillation, aiming to prevent recurrence of tumors.
- Beyond these primary indications, mitomycin has been explored and used in various other solid tumors, including squamous cell carcinoma of the head and neck, breast cancer, and certain types of non-small cell lung cancer, typically as part of multi-agent regimens or in specific treatment protocols.
- Its role is usually reserved for palliative settings or when other treatment options have failed, given its significant toxicity profile.
- The precise application and dosage depend heavily on the specific cancer type, stage, and the patient's overall health status, always balancing potential benefits against substantial risks.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of mitomycin varies significantly based on the route of administration, the specific cancer being treated, and the patient's hematologic status. For intravenous (IV) administration in disseminated adenocarcinomas, a common regimen involves a single dose of 20 mg/m² administered every 6 to 8 weeks, provided adequate hematologic recovery. Alternatively, some protocols suggest 5 to 10 mg/m² daily for 5 days, with the cycle repeated after a 2 to 3-week interval, again contingent on bone marrow function. Strict adherence to blood count monitoring, particularly nadir counts, is crucial for dose adjustment and determining eligibility for subsequent cycles. For intravesical administration in superficial bladder cancer, typical doses range from 20 to 40 mg instilled into the bladder, usually once weekly for 6 to 8 weeks, sometimes followed by monthly maintenance instillations. Patients are generally instructed to retain the solution in the bladder for a specified duration (e.g., 2 hours). Precise dosing protocols must be followed as outlined by the prescribing oncologist, considering cumulative myelosuppression and potential renal toxicity. |
Safety & Warnings
Common Side Effects
- Mitomycin is associated with a wide range of significant and potentially severe side effects, predominantly due to its cytotoxic nature.
- The most common and dose-limiting adverse effect is myelosuppression, leading to leukopenia, thrombocytopenia, and anemia, which is often delayed and cumulative.
- Gastrointestinal toxicities are frequent, including nausea, vomiting, stomatitis, anorexia, and diarrhea.
- Dermatological reactions can manifest as alopecia, rash, pruritus, and desquamation, with severe local tissue damage (necrosis, ulceration) possible upon intravenous extravasation.
- Renal toxicity, notably Hemolytic Uremic Syndrome (HUS), is a serious and potentially fatal complication characterized by microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure.
- Pulmonary toxicity, such as interstitial pneumonitis and pulmonary fibrosis, can also occur and be life-threatening.
- Other reported side effects include fever, malaise, fatigue, headache, and transient elevations in liver enzymes.
- Close monitoring for these adverse events is essential during and after treatment.
Serious Warnings
- Black Box Warning: MITOMYCIN C IS ASSOCIATED WITH SEVERE AND POTENTIALLY FATAL TOXICITIES. 1. **MYELOSUPPRESSION:** Mitomycin causes profound, cumulative, and delayed bone marrow suppression, manifesting as leukopenia, thrombocytopenia, and anemia. This myelosuppression can be prolonged, with nadirs often occurring 4-8 weeks after treatment initiation, and can lead to life-threatening infections and hemorrhage. Complete blood counts (CBCs) with differential and platelet counts must be performed frequently, especially before each dose and for at least 8 weeks following the last dose. Dosage must be adjusted or withheld based on hematologic status to prevent severe complications. 2. **HEMOLYTIC UREMIC SYNDROME (HUS):** Mitomycin therapy has been associated with a potentially fatal, acute syndrome characterized by microangiopathic hemolytic anemia (schistocyte formation, falling hemoglobin), thrombocytopenia, and irreversible renal failure. This complication, often referred to as Mitomycin-induced HUS, can occur at any point during or after therapy, with increased risk observed with higher cumulative doses. Patients should be closely monitored for signs and symptoms of HUS, including changes in renal function, and treatment should be immediately discontinued if this syndrome is suspected or diagnosed. 3. **PULMONARY TOXICITY:** Interstitial pneumonitis and pulmonary fibrosis, which can be life-threatening, have been reported in patients receiving mitomycin. Patients should be monitored for new or worsening respiratory symptoms, including cough, dyspnea, and hypoxia. Mitomycin should be discontinued if evidence of pulmonary toxicity develops, and appropriate supportive care initiated. Patients with pre-existing lung disease or those receiving concurrent pulmonary-toxic agents may be at increased risk. These severe adverse events necessitate meticulous patient selection, vigilant monitoring, and careful dose management.
- Patients receiving mitomycin must be under close medical supervision due to its high toxicity profile.
- One critical warning pertains to extravasation during intravenous administration; mitomycin is a potent vesicant, and accidental leakage from the vein can cause severe local pain, swelling, blistering, and potentially lead to necrosis and ulceration of the surrounding tissue.
- Immediate and appropriate management protocols for extravasation are vital.
- The drug's toxicity, particularly myelosuppression and renal dysfunction, is cumulative, necessitating careful evaluation of previous treatment history and existing organ function before each dose.
- Patients with pre-existing lung disease or those receiving concurrent radiation to the chest or other cytotoxic agents may face an elevated risk of pulmonary toxicity.
- Mitomycin also induces immunosuppression, increasing susceptibility to infections, and patients should be advised to report any signs of infection promptly.
- Additionally, impairment of fertility in both men and women is a known risk, and counseling on fertility preservation options should be considered prior to treatment initiation.
How it Works (Mechanism of Action)
Mitomycin is an antitumor antibiotic that functions as a potent DNA alkylating agent. Its antineoplastic activity is initiated following intracellular enzymatic reduction, which converts the parent compound into an active bifunctional or trifunctional alkylating metabolite. This activated form then cross-links DNA strands at various sites, primarily through N7 of guanine, and inhibits DNA synthesis. To a lesser extent, it also interferes with RNA and protein synthesis. These DNA cross-links are particularly effective in preventing DNA replication and transcription, thereby disrupting essential cellular processes vital for cancer cell proliferation. As a non-cell cycle specific agent, mitomycin can exert its cytotoxic effects on cells in any phase of the cell cycle, contributing to its broad spectrum of activity against various solid tumors. The resulting genomic damage leads to cell cycle arrest and ultimately triggers apoptosis in rapidly dividing malignant cells.